-
公开(公告)号:US06956052B2
公开(公告)日:2005-10-18
申请号:US10247096
申请日:2002-09-19
申请人: Arija A. Bergmanis , Michael Clare , Joyce Z. Crich , Lifeng Geng , Timothy J. Hagen , Gunnar J. Hanson , Stephen C. Houdek , He Huang , Donna M. Iula , Francis J. Koszyk , Shuyuan Liao , Scott B. Mohler , Maria Nguyen , Richard A. Partis , Michael A. Stealey , Michael B. Tollefson , Richard M. Weier , Xiangdong Xu , Dominique Bonafoux , Theresa R. Fletcher , Bruce C. Hamper , Patrick J. Lennon , Subo Liao , Suzanne Metz , David S. Oburn , Thomas J. Owen , Angela M. Scates , Michael L. Vazquez , Serge G. Wolfson
发明人: Arija A. Bergmanis , Michael Clare , Joyce Z. Crich , Lifeng Geng , Timothy J. Hagen , Gunnar J. Hanson , Stephen C. Houdek , He Huang , Donna M. Iula , Francis J. Koszyk , Shuyuan Liao , Scott B. Mohler , Maria Nguyen , Richard A. Partis , Michael A. Stealey , Michael B. Tollefson , Richard M. Weier , Xiangdong Xu , Dominique Bonafoux , Theresa R. Fletcher , Bruce C. Hamper , Patrick J. Lennon , Subo Liao , Suzanne Metz , David S. Oburn , Thomas J. Owen , Angela M. Scates , Michael L. Vazquez , Serge G. Wolfson
IPC分类号: A61K31/416 , A61K31/4178 , A61K31/4245 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/551 , A61P19/02 , A61P25/04 , A61P29/00 , A61P35/00 , C07D231/54 , C07D333/62 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04
CPC分类号: C07D403/12 , C07D231/54 , C07D333/62 , C07D401/12 , C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要: The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.
-
公开(公告)号:US07186743B2
公开(公告)日:2007-03-06
申请号:US11113926
申请日:2005-04-25
申请人: Arija A. Bergmanis , Michael Clare , Joyce Z. Crich , Lifeng Geng , Timothy J. Hagen , Gunnar J. Hanson , Stephen C. Houdek , He Huang , Donna M. Iula , Francis J. Koszyk , Shuyuan Liao , Scott B. Mohler , Maria Nguyen , Richard A. Partis , Michael A. Stealey , Michael B. Tollefson , Richard M. Weier , Xiangdong Xu , Dominique Bonafoux , Theresa R. Fletcher , Bruce C Hamper , Patrick J. Lennon , Subo Liao , Suzanne Metz , David S. Oburn , Thomas J. Owen , Angela M. Scates , Michael L. Vazquez , Serge G. Wolfson
发明人: Arija A. Bergmanis , Michael Clare , Joyce Z. Crich , Lifeng Geng , Timothy J. Hagen , Gunnar J. Hanson , Stephen C. Houdek , He Huang , Donna M. Iula , Francis J. Koszyk , Shuyuan Liao , Scott B. Mohler , Maria Nguyen , Richard A. Partis , Michael A. Stealey , Michael B. Tollefson , Richard M. Weier , Xiangdong Xu , Dominique Bonafoux , Theresa R. Fletcher , Bruce C Hamper , Patrick J. Lennon , Subo Liao , Suzanne Metz , David S. Oburn , Thomas J. Owen , Angela M. Scates , Michael L. Vazquez , Serge G. Wolfson
IPC分类号: A61K31/416 , A61K31/454 , A61K31/5395 , A61K31/429 , A61K31/433 , A61K31/506 , A61K31/496
CPC分类号: C07D403/12 , C07D231/54 , C07D333/62 , C07D401/12 , C07D401/14 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要: The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.
摘要翻译: 本发明涉及取代的吡唑基衍生物,包含这些的组合物,中间体,制备取代的吡唑基衍生物的方法,以及用于治疗癌症,炎症和炎症相关疾病如关节炎的方法。
-
公开(公告)号:US06890937B2
公开(公告)日:2005-05-10
申请号:US10337942
申请日:2003-01-07
申请人: Thomas E. Barta , Daniel P. Becker , Louis J. Bedell , Terri L. Boehm , Jeffery N. Carroll , Gary A. DeCrezcenzo , Theresa R. Fletcher , John N. Freskos , Daniel P. Getman , Gunnar J. Hanson , Susan L. Hockerman , Carol P. Howard , Stephen A. Kolodziej , Madeleine H. Li , Joseph J. McDonald , Deborah A. Mischke , Patrick B. Mullins , Joseph G. Rico , Nathan W. Stehle , Clara I. Villamil
发明人: Thomas E. Barta , Daniel P. Becker , Louis J. Bedell , Terri L. Boehm , Jeffery N. Carroll , Gary A. DeCrezcenzo , Theresa R. Fletcher , John N. Freskos , Daniel P. Getman , Gunnar J. Hanson , Susan L. Hockerman , Carol P. Howard , Stephen A. Kolodziej , Madeleine H. Li , Joseph J. McDonald , Deborah A. Mischke , Patrick B. Mullins , Joseph G. Rico , Nathan W. Stehle , Clara I. Villamil
IPC分类号: A61K31/16 , A61K31/167 , A61K31/27 , A61K31/35 , A61K31/351 , A61K31/357 , A61K31/366 , A61K31/38 , A61K31/381 , A61K31/382 , A61K31/39 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/444 , A61K31/445 , A61K31/4465 , A61K31/4525 , A61K31/454 , A61K31/496 , A61K31/505 , A61K31/506 , A61K31/5375 , A61K31/54 , A61K31/541 , A61P1/02 , A61P1/04 , A61P9/10 , A61P13/00 , A61P19/00 , A61P19/02 , A61P25/28 , A61P27/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P43/00 , C07C317/44 , C07C319/06 , C07D211/66 , C07D211/94 , C07D211/96 , C07D239/04 , C07D279/06 , C07D309/08 , C07D309/12 , C07D319/06 , C07D327/02 , C07D333/38 , C07D335/02 , C07D337/04 , C07D401/06 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D521/00 , C07D211/06
CPC分类号: C07D231/12 , A61K31/19 , A61K31/4166 , A61K31/421 , A61K31/426 , C07C317/44 , C07D207/48 , C07D211/54 , C07D211/66 , C07D211/86 , C07D211/94 , C07D211/96 , C07D225/02 , C07D233/56 , C07D239/04 , C07D249/08 , C07D263/06 , C07D265/06 , C07D279/06 , C07D281/08 , C07D309/08 , C07D309/28 , C07D319/06 , C07D325/00 , C07D335/02 , C07D337/04 , C07D401/06 , C07D401/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.
摘要翻译: 公开了一种处理方法,其包括施用有效量的显示出一种或多种基质金属蛋白酶(MMP)酶如MMP-2,MMP-9和MMP-13的优异抑制活性的芳香族砜异羟肟酸,同时显示 至少对具有与病理基质金属蛋白酶活性相关的病症的宿主的MMP-1的抑制显着降低。 施用的酶抑制剂在结构上对应于下式(I)或其药学上可接受的盐,其中R 1和R 2都是氢或R 2, 1和R 2与它们所键合的原子一起形成在环中含有一个,两个或三个杂原子的5-至8-元环,其为氧,硫, 或氮气。 式(I)中的R 3是任选取代的芳基或任选取代的杂芳基。 还公开了具有这些选择活性的金属蛋白酶抑制剂化合物,制备这种化合物的方法和使用抑制剂的药物组合物。
-
-